Shareholder Tools

Genmab News

Genmab News

News Category

Year

Date	Title	View
Sep 13, 2019	Genmab Announces Positive Topline Results in Phase III Study of Daratumumab in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma	190913_CA45_CANDOR
Sep 13, 2019	Detailed Results from the Phase III ASCLEPIOS I & II Studies of Ofatumumab in Patients with Relapsing Multiple Sclerosis Presented at ECTRIMS	190913_CA44_Ofatumumab Data at ECTRIMS
Sep 09, 2019	Genmab and Tempus Enter into Strategic Collaboration Agreement	190909_i12_Tempus
Aug 30, 2019	Genmab’s Partner for Ofatumumab, Novartis, Reports that Ofatumumab Demonstrates Superiority Versus Teriflunomide in Two Head-to-Head Phase III Multiple Sclerosis Studies	190830_CA43_Ofatumumab RMS Data
Aug 22, 2019	Genmab Announces Approval of DARZALEX® (daratumumab) in Frontline Multiple Myeloma in Japan	190822_CA_42_ALCYONE Japan approval
Aug 21, 2019	Genmab Announces Preliminary Data to be Presented at IASLC 2019 World Conference on Lung Cancer	190821_i11_EV at WCLC
Aug 21, 2019	Genmab A/S has published its Articles of Association	Articles of Association - August 20, 2019 (UK)
Aug 20, 2019	Capital Increase in Genmab as a Result of Employee Warrant Exercise	190820_CA41_warrant exercise
Aug 19, 2019	Daratumumab Abstracts Selected for Presentation at 17th International Myeloma Workshop	190819_i10_IMW
Aug 14, 2019	Genmab Announces Financial Results for the First Half of 2019 and Updates 2019 Financial Guidance	190814_CA40_Q2 2019 Interim Report
Jul 23, 2019	Genmab A/S has published its Articles of Association	Articles of Association - July 17 2019 II (UK)
Jul 23, 2019	Genmab Announces the Closing of Over-Allotment Option in Initial Public Offering of American Depositary Shares (ADSs) in the United States and Registration of Capital Increase	190723_CA39_Overallotment Closing
Jul 22, 2019	Genmab A/S has published its Articles of Association	Articles of Association - 17 July 2019 UK
Jul 22, 2019	Genmab Announces the Completion of its Initial Public Offering of American Depositary Shares (ADSs) in the United States and Registration of Capital Increase	190722_CA38_Closing
Jul 19, 2019	Major Shareholder Announcement	190719_CA37_Major Shareholder Blackrock Increase
Jul 19, 2019	Genmab Announces Full Exercise of Underwriters’ Over-Allotment Option in Initial Public Offering	190719_CA36_over-allotment option
Jul 19, 2019	Genmab Announces Submission of Extension of Marketing Authorization to European Medicines Agency for Subcutaneous Formulation of Daratumumab	190719_i09_Dara SC EMA Submission
Jul 17, 2019	Genmab Prices its Initial Public Offering of American Depositary Shares (ADSs) in the United States	190718_CA35_Pricing
Jul 16, 2019	Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2019	190716_CA34_Dara Q2 Sales
Jul 12, 2019	Genmab Announces Submission of Biologics License Application to U.S. FDA for Subcutaneous Formulation of Daratumumab	190712_CA33_Dara SC FDA Submission
Jul 12, 2019	Genmab and BliNK Biomedical Enter into Commercial License Agreement	190712_i08_BliNK
Jul 09, 2019	Genmab Commences Public Offering of American Depositary Shares (ADSs) in the United States	190709_CA32_Launch Announcement
Jul 08, 2019	Genmab Announces Positive Topline Results in the Phase II GRIFFIN Study of Transplant Eligible, Newly Diagnosed Patients with Multiple Myeloma Treated with Daratumumab in Combination with Lenalidomide, Bortezomib, and Dexamethasone	190708_CA31_GRIFFIN Data
Jun 27, 2019	Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma	190627_CA30_MAIA Approval
Jun 26, 2019	Genmab A/S has published its Articles of Association	Articles of Association - June 25 2019 (UK)

Shareholder Tools